AstraZeneca plc (ADR) (NYSE:AZN) presented positive data on Tuesday from its Phase 3 SOLO-2 trial of LYNPARZA for the treatment of germline BRCA-mutated (gBRCA), platinum-sensitive, relapsed ovarian cancer. The trial met its primary endpoint of investigator-assessed progression-free survival (PFS) of 19.1 months compared with 5.5 months for those on placebo. Competitor, TESARO Inc (NASDAQ:TSRO) bore the brunt of AstraZeneca’s success, with shares closing the week down 13% to $149.99.
Shares of Catalyst Pharmaceuticals, Inc. (Nasdaq:CPRX) got a welcome boost on Wednesday following news that it met the primary endpoints in its Phase 2/3 trial of Firdapse as a treatment for myasthenia gravis patients with anti-MuSK antibodies (MuSK-MG). Shares closed the week up 39% to $1.54.
AveXis, Inc. (NASDAQ:AVXS) also impressed with top-line data late on Thursday from its Phase 1 trial of AVXS-101 in spinal muscular atrophy (SMA) Type 1, with all patients event-free at 13.6 months of age, sending shares up to close 15% higher on Friday at $84.00.
To round out the week on the clinical data front, Amgen (NASDAQ:AMGN) released much awaited data on Friday from its FOURIER cardiovascular outcomes trial for its approved cholesterol drug Repatha. The company had already notified in early February that both primary and secondary endpoints were met so investors were eagerly awaiting the actual data from the trial. The 15% reduction in cardiovascular events (angina, coronary revascularization, heart attack, stroke or cardiovascular death) was below investor expectations which saw shares closing the session down 6.4% to $168.61. Esperion Therapeutics Inc (NASDAQ:ESPR), which saw its shares spike 29% in early February when news that both primary and secondary endpoints were met, saw its shares reverse, closing Friday’s session down 20% to $23.67.
On the offering front shares of Editas Medicine, Inc. (NASDAQ:EDIT), Zosano Pharma Corporation (NASDAQ:ZSAN) , Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) and Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) all suffered from sharply discounted offerings. However, Aurinia is still well up over 100% since the start of March.
Upcoming March and April catalysts on watch noted below: